Conference News

SABCS 2024 Can Some Patients Safely Skip Postmastectomy Radiation? Most women with intermediate-risk breast cancer can safely skip chest wall irradiation after mastectomy and avoid the risks for chest wall pain, fibrosis, heart damage, and lung cancer.
News, January 09, 2025
SABCS 2024 CDK 4/6 Blocker Prolongs Survival in HER2+ Breast Cancer “Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.
News, January 09, 2025
New Ideas on PsA Pathogenesis May Drive New Treatments Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may become altered, leading to a worsening of symptoms.
News, January 07, 2025
MSWS 2024 Inflammation Now the Key Target for Seborrheic Dermatitis Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that inflammation is considered key to the underlying pathology.
News, January 06, 2025
Combined Psoriasis/PsA Clinics: Potential and Pitfalls Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for dermatology and rheumatology patients.
News, January 02, 2025
Why Sex and Gender Are Important Biomarkers in PsA Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a biomarker, one researcher said.
News, December 24, 2024
AES 2024 AI Catches Missing MRI Lesions Open-source algorithm achieves a positive predictive value of nearly 70% for focal cortical dysplasia.
News, December 23, 2024
ASH 2024 Hemophilia A: Bleeds Plummet After Experimental Gene Therapy
News, December 23, 2024
AHA 2024 Soaring Pacemaker Demand Spurs Controversial New Approach When there aren't enough cardiac devices for everybody who needs one, does it make sense to start refurbishing older technology and reusing it?
News, December 23, 2024
ACR 2024 Post-Exertional Malaise in Fatiguing Diseases: What to Know A new finding of post-exertional malaise in 20% of people with fibromyalgia might be an overestimate, but when post-exertional malaise is present, extreme caution is needed around prescribing exercise.
News, December 20, 2024
ACR 2024 IL-6 Receptor Inhibitors Show Early Promise for CPPD Studies have suggested that IL-1 beta activation leads to IL-6 production, which could provide an alternative to current therapeutic strategies.
News, December 20, 2024
ACR 2024 Genetic Markers May Predict TNF Inhibitor Response in RA Genetic markers may help predict response to TNF inhibitor therapy in rheumatoid arthritis, potentially leading to more personalized and effective treatment strategies.
Clinical Summary, December 20, 2024
SABCS 2024 HRQOL the Same With CDK4/6 Inhibitors in 1st or 2nd Line An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar regardless of treatment timing.
News, December 20, 2024
SABCS 2024 T-DXd Preserves QOL, Brain Function in HER2+ Breast Cancer Deterioration-free rates at 1 year were comparable for patients with or without brain metastases.
News, December 20, 2024
ASH 2024 Follicular Lymphoma Therapy Shows Cost-Time Trade-Offs Liso-cel outperformed mosunetuzumab in progression-free survival, healthcare resource usage, and quality of life but came with a much higher overall cost, a modeling study found.
Clinical Summary, December 20, 2024
ASH 2024 MCL: Post-Remission, Skip Stem Cell Transplant? Patients who had MRD negativity in first remission and randomly assigned to stem cell transplant or maintenance therapy alone showed no differences in survival outcomes.
News, December 19, 2024
SABCS 2024 Can AI Tool Guide CDK4/6 Inhibitor Use in Breast Cancer? A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in HR+/HER2– advanced breast cancer.
News, December 19, 2024
AES 2024 Online Intervention Offers Hope for Epilepsy Stigma Four sequential modules address stress, identifying stigma, cognitive behavioral strategies, and problem-solving.
News, December 19, 2024
SABCS 2024 T-DXd Effective in HR+/HER2-Low BC After Endocrine Failure New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid progression on endocrine therapy, with benefit seen across all subgroups.
News, December 19, 2024
SABCS 2024 Nab-Paclitaxel Shows Edge in High-Risk BC Subgroup Weekly nab-paclitaxel demonstrated improved disease-free survival compared with biweekly standard paclitaxel in HR+/HER2– early breast cancer patients with lower recurrence scores.
News, December 19, 2024

No Results